NEW YORK (GenomeWeb News) – Veracyte today priced its initial public offering of 5 million shares at $13 per share.

The South San Francisco, Calif.-based firm is expected to begin trading today on the Nasdaq Global Market under the symbol "VCYT." It will realize gross proceeds of $65 million from the offering, though the underwriters of the IPO have a 30-day option to purchase 750,000 additional shares to cover any over-allotments.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: transcript patterns in drug-resistant cancer cells, function of high-altitude adaption gene, and more.

Monitoring gene expression changes could help sniff out athletes using performance-enhancing drugs, New Scientist says.

The University of Southern California lodges a cross-complaint in its legal dispute with the University of California, San Diego, over a large Alzheimer's disease project.

A National Science Foundation-funded project aims to give researchers access to a network many times faster than the Internet.

Sep
17
Sponsored by
Omicia

This online seminar will provide examples of how commercial and hospital-affiliated clinical labs are successfully developing and deploying high-throughput next-generation sequencing-based testing services for genetic diseases. 

Oct
15
Sponsored by
Parabase

This webinar will discuss the benefits of a rapid targeted next-generation sequencing (TNGS) panel, using dried blood spots, for second-tier newborn metabolic and hearing loss screening and its immediate utility for high-risk diagnostic testing in the neonatal intensive care unit.